A phase 1 trial of sapanisertib and telaglenastat (CB-839) in patients with advanced NSCLC (NCI 10327): Results from dose escalation Meeting Abstract
| Authors: | Riess, J.; Frankel, P.; Massarelli, E.; Nieva, J.; Lai, W. C. V.; Koczywas, M.; Shackelford, D.; Lanza, I.; Reid, J. M.; Gonsalves, W. I.; Remick, A. J.; Gandara, D. R.; Piekarz, R.; Lara, P. N.; Newman, E.; Villalona-Calero, M.; Paik, P. |
| Abstract Title: | A phase 1 trial of sapanisertib and telaglenastat (CB-839) in patients with advanced NSCLC (NCI 10327): Results from dose escalation |
| Meeting Title: | 2022 World Conference on Lung Cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 17 |
| Issue: | 9 Suppl. |
| Meeting Dates: | 2022 Aug 6-9 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-09-01 |
| Start Page: | S91 |
| End Page: | S92 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2022.07.153 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: MA13.08 -- Located within section named "MA13 Update On ROS1 Inhibitors And New Pathways" -- Accession Number: 159037399 -- Entry Date: In Process -- Revision Date: 20220913 -- Publication Type: Article -- Supplement Title: 2022 Supplement -- Journal Subset: Biomedical; Blind Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101274235. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
